Evidence map›Paper›PMID 35920287›Full record

ReviewESC heart failure2022

Atrial cardiomyopathy: from cell to bedside.

Mengmeng Li, Yuye Ning, Gary Tse, Ardan M Saguner, Meng Wei, John D Day, Guogang Luo, Guoliang Li

Open access · goldAbstract readReview
In one paragraph

Review in ESC heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Evidence for a role of adverse sarcomere signaling in atrial fibrillation induction.Journal of molecular and cellular cardiology plus · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Observational
  9. Review
  10. Review
  11. Review
  12. A novel technique for vein of Marshall blood sampling and its application in assessing atrial remodeling in atrial fibrillation.Clinical research in cardiology : official journal of the German Cardiac Society · 2025
    Article
  13. Review
  14. Atrial cardiomyopathy.ESC heart failure · 2025
    Article
  15. Gut microbiota and atrial cardiomyopathy.Frontiers in cardiovascular medicine · 2025
    Review
  16. Atrial Cardiomyopathy: From Diagnosis to Treatment.Reviews in cardiovascular medicine · 2025
    Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 4 countries.

Mengmeng LiStroke Centre and Department of Neurology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Yuye NingStroke Centre and Department of Neurology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Gary TseKent and Medway Medical School, Canterbury, UK.
Ardan M SagunerArrhythmia Division, Department of Cardiology, University Heart Centre, University Hospital Zurich, Zurich, Switzerland.
Meng WeiStroke Centre and Department of Neurology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
John D DayDepartment of Cardiology, St. Mark's Hospital, Salt Lake City, UT, USA.
Guogang LuoStroke Centre and Department of Neurology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Guoliang LiDepartment of Cardiovascular Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.ORCID 0000-0002-2352-9404
First Affiliated Hospital of Xi'an Jiaotong University · CNMedway School of Pharmacy · GBShanxi Medical University · CNSt. Mark's Hospital · USUniversity Hospital of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atrial cardiomyopathy refers to structural and electrical remodelling of the atria, which can lead to impaired mechanical function. While historical studies have implicated atrial fibrillation as the leading cause of cardioembolic stroke, atrial cardiomyopathy may be an important, underestimated contributor. To date, the relationship between atrial cardiomyopathy, atrial fibrillation, and cardioembolic stroke remains obscure. This review summarizes the pathogenesis of atrial cardiomyopathy, with a special focus on neurohormonal and inflammatory mechanisms, as well as the role of adipose tissue, especially epicardial fat in atrial remodelling. It reviews the current evidence implicating atrial cardiomyopathy as a cause of embolic stroke, with atrial fibrillation as a lagging marker of an increased thrombogenic atrial substrate. Finally, it discusses the potential of antithrombotic therapy in embolic stroke with undetermined source and appraises the available diagnostic techniques for atrial cardiomyopathy, including imaging techniques such as echocardiography, computed tomography, and magnetic resonance imaging as well as electroanatomic mapping, electrocardiogram, biomarkers, and genetic testing. More prospective studies are needed to define the relationship between atrial cardiomyopathy, atrial fibrillation, and embolic stroke and to establish a prompt diagnosis and specific treatment strategies in these patients with atrial cardiomyopathy for the secondary and even primary prevention of embolic stroke.

Indexed as

Atrial FibrillationCardiomyopathiesEmbolic StrokeStrokeHeart AtriaHumansAtrial cardiomyopathyAtrial fibrillationDiagnosisEmbolic strokePathogenesis

Identifiers

PMID35920287
PMCPMC9773734
OpenAlexW4289545082

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.